Menu
Our website is currently being updated and you may experience some limited functionality at this time.
Menu
Menu
Our website is currently being updated and you may experience some limited functionality at this time.
ProAxsis Limited is a global In-Vitro diagnostics company based in Northern Ireland.
Founded in August 2013 by Professor Brian Walker and Dr Lorraine Martin, ProAxsis has won numerous awards for entrepreneurialism (2014), innovative business of the year (2018) and Best Established Small Business at the2022 Belfast Telegraph Business Awards and continues to push the boundaries of diagnostic key targets in respiratory and other aligned key areas of population health.
ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialization Group.
ProAxsis Limited is a global In-Vitro diagnostics company based in Northern Ireland.
The company promotes a range of assay kits designed for the specific measurement of active protease biomarkers of disease. Our easy-to-use tests incorporate patented technology called “ProteaseTags®”; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence.
The company promotes a range of assay kits designed for the specific measurement of active protease biomarkers of disease. Our easy-to-use tests incorporate patented technology called “ProteaseTags ®”; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence.
The company has developed activity-based immunoassays targeting Neutrophil Elastase(NE) and Proteinase 3, biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, bronchiectasis, and cystic fibrosis.
This technology has been translated into a point-of-care test (NEATstik ®), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik ® enables identification of patients with airway bacterial infection and those patients at highest risk of future exacerbations over the subsequent 12 months.
ProAxsis continues to pursue other key areas including bone health, coagulation markers and COVID anti-bodies (in conjunction with global respiratory leader, AstraZeneca).
ProAxsis offers clinical support through in-house sample analysis at its purpose-built laboratory facility in Belfast. These facilities are currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.
ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialization Group.
The company has developed activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, bronchiectasis, and cystic fibrosis.
This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of future exacerbations over the subsequent 12 months.
In addition to measuring biomarkers of respiratory inflammation, ProAxsis continues to pursue other key areas including but not limited to, bone health and COVID anti-bodies (in conjunction with global respiratory leader, AstraZeneca).
Additionally, ProAxsis offers clinical support through in-house sample analysis at its purpose-built laboratory facility in Belfast. These facilities are currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.
Founded in August 2013 by Professor Brian Walker and Dr Lorraine Martin, ProAxsis has won numerous awards for entrepreneurialism (2014) and innovative business of the year (2018) and continues to push the boundaries of diagnostic key targets in respiratory and other aligned key areas of population health.
Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.
ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialisation Group.
Curabitur vehicula tincidunt sapien velcac dolore laudantium.
Copyright © 2023 ProAxsis. All Rights Reserved
